Vaccine News and Research

Latest Vaccine News and Research

Agenus closes previously announced acquisition of 4-Antibody

Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

13 Feb 2014

State highlights: More states gearing up to combine Medicare, Medicaid; vaccination exemptions still considered by many states; likely Texas democratic Gov. Candidate backs 20-week abortion ban

A selection of health policy stories from California, Texas, Colorado, Virginia, North Carolina, Florida and Connecticut.

13 Feb 2014

International study examines link between infections and ischemic stroke in children

Common infections are associated with a significantly higher chance of stroke in children, but routine vaccinations may help decrease risk, according to preliminary research (abstract 39) presented at the American Stroke Association's International Stroke Conference 2014.

12 Feb 2014

First Edition: February 12, 2014

Today's headlines include reports about President Barack Obama's comments yesterday on his administration's decision to decision to give mid-sized businesses more time to comply with the health law's employer mandate.

12 Feb 2014

Researchers examine how evolution relates to health

February 12 marks the birth of the 19th century naturalist Charles Darwin, who launched the scientific study of evolution. While Darwin's theory laid the groundwork, ongoing studies have deepened our understanding of evolution, including how it relates to health. Research funded by the National Institutes of Health has helped answer many questions about evolution, health and medicine. Here's a sampling.

12 Feb 2014

Global decision-making has disastrous effect on human health

The organisation of political power within and between nations and citizens fails to protect the public's health, according to the findings of a new Commission from The Lancet and the University of Oslo, published today [Tuesday 11 February].

12 Feb 2014

Biologists demonstrate highly effective method for delivering HIV-fighting antibodies

In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies to mice-a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously.

12 Feb 2014

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise.

11 Feb 2014

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis Inc. today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational increase of 9%, with foreign currency having a negative impact of 2 percentage points.

11 Feb 2014

Henry Schein net sales increase 4.9% to $2.5 billion in fourth quarter 2013

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record financial results for the quarter ended December 28, 2013.

11 Feb 2014

Unvaccinated flu patients need more intensive care

A snapshot of patients who required care at Duke University Hospital during this year's flu season shows that those who had not been vaccinated had severe cases and needed the most intensive treatment.

11 Feb 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

Viewpoints: CBO report on health law: Damaging the labor market or freeing workers from 'insurance trap'?

There are 7.8 million Americans working part-time who want full-time work, including a fry cook whose restaurant cut his hours to avoid Affordable Care Act mandates and confronted President Obama in an online Google Q&A last week: "We can't survive. It's not a living." Mr. Obama changed the subject to raising the minimum wage. But he can't dodge reality forever as the evidence piles up that ObamaCare is harming the labor market.

6 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

95% of adults die annually from vaccine preventable diseases

While adults make up 95 percent of those who die annually from vaccine preventable diseases, a new study from the University of Colorado School of Medicine shows their vaccination rates remain stubbornly low, representing a growing public health concern.

5 Feb 2014

First Edition: February 4, 2014

Today's headlines include progress reports on health exchanges in Washington state and New York as well as poll results on Virginia's Medicaid Expansion.

4 Feb 2014

Discovery may have implications for HIV vaccine research

NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research.

4 Feb 2014

Admedus' HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial

Admedus today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.

3 Feb 2014